Open AccessChemotherapy during pregnancy: effect of anthracyclines on fetal and maternal cardiac function
Author(s) -
GZIRI MINA MHALLEM,
DEBIÈVE FRÉDÉRIC,
DE CATTE LUC,
MERTENS LUC,
BARREA CATHERINE,
VAN CALSTEREN KRISTEL,
HAN SILENY N.,
HEYNS LIESBETH,
AMANT FRÉDÉRIC
Publication year - 2012
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1111/j.1600-0412.2012.01524.x
Subject(s) - medicine , chemotherapy , pregnancy , cardiac function curve , fetus , obstetrics , fetal heart , gynecology , heart failure , genetics , biology
Chemotherapy and especially anthracyclines are associated to cardiotoxicity. To assess this potential risk during pregnancy a clinical case–control trial was conducted. Maternal cardiac function, fetal Doppler and fetal cardiac function were evaluated before and after chemotherapy. Maternal cardiac function was assessed by echocardiography before and after the third cycle of anthracyclines and compared with a control group of 10 non‐pregnant women matched for age, type of cancer and anthracycline treatment. Ten fetuses exposed to chemotherapy were compared with 10 control fetuses matched for gestational age and gender. Biometry, amniotic fluid index, fetal Doppler and cardiac function were assessed before and after each cycle of chemotherapy. In all, 108 fetal ultrasounds scans were performed before and after 36 cycles of chemotherapy. Anthracycline exposure did not result in acute maternal and fetal cardiac dysfunction in this small cohort study.